GenVec, Inc. company was founded in 1992 and is based in Gaithersburg, Maryland. GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, wfor the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, it is developing TherAtoh, a preclinical program involving the delivery of the human atonal gene for the production of therapeutic proteins by cells in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2. It has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATH'S malaria vaccine initiative, the U.S. naval medical research center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California. AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores.

Elixir Pharmaceuticals concocts treatments targeting metabolic diseases and disorders. Dedicated to the discovery, development, and commercialization of treatments for such diseases as diabetes and obesity, the company has taken a dual approach to its work: licensing products from other pharmaceutical companies for development and pursuing proprietary products. Product candidates currently under development include Glinsuna and Metgluna as treatment for type 2 diabetes and a ghrelin antagonist as a treatment for a range of metabolic disorders (all in phase III testing). The company is also exploring the use of sirtuin modulators to treat metabolic disorders, cancer, and neurodegenerative disease.

Argenta Discovery hopes to find some help for those suffering from respiratory diseases. The pharmaceutical research and development company's quest focuses on discovering treatments for allergic asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. With seven products in various preclinical and clinical testing stages, Argenta has ongoing strategic alliances with AstraZeneca, Domantis, and Dr. Reddy's to help develop certain compounds once they clear phase II trials. Argenta also performs fee-for-service research for third-party clients which have included Genentech, Zafgen, Antisoma, and Novartis. Argenta was spun off from Aventis (now Sanofi-Aventis) in 2000.

Endo Pharmaceuticals Holdings Inc. was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania. Endo Pharmaceuticals Holdings Inc., a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company's products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company's generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited.

NeuroNova wants to recharge neurons. The biopharmaceutical company is engaged in the research and development of therapies to help regenerate central nervous system cells in patients with Alzheimer's disease, Parkinson's disease, and other disorders. Its research focuses on developing drugs that will stimulate endogenous stem and progenitor cells to restore damaged areas of the brain. The company has two drug candidates nearing clinical development in addition to other compounds in the discovery and pre-clinical phases. NeuroNova was founded in 1998 and is financed by Swedish venture capital companies HealthCap, Scandinavian Life Science Venture, and Investor Growth Capital.

Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

Owners (and spouses) Tei Fu Chen and Oi-Lin Chen started Sunrider International in 1982. Sunrider Corporation has blended bits of traditional Chinese herbal medicine with modern multilevel marketing. The company sells health, beauty, food, and household products enhanced with herbs and herbal extracts. Its brands include Kandesn, Vitalite, SunBright, and SunSmile. Sunrider has manufacturing operations in China, Singapore, Taiwan, and the US. Its products are sold in more than 40 countries through multilevel marketing via distributors and directly to customers. In China, its products are sold in thousands of franchised stores to avoid regulations on direct-selling. It plans to copy that model in Japan.

England's Northwest region is a hotbed of biotechnology growth. It's Bionow's job to make the region even hotter -- and turn it into the center of biomanufacturing in Europe. Funded by the Northwest Development Agency, Bionow promotes and encourages growth in the area, which is already home to a plethora of biomanufacturing facilities for companies such as AstraZeneca, Eli Lilly, and Chiron Vaccines. Bionow offers information on companies, facilities, and services in the region, promotes educational and networking events, and organizes overseas trade missions. The Northwest also has several academic research centers in Liverpool and Manchester.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.